Por lo Qué Hasta la Obtención de los Resultados Completos ... Más la Elaboración del Dossier ... Más la Evaluación de las Agencias ... Nos Podemos Ir al 2027 .
04 febrero 2009
Sociedad Española de Oncología Médica (SEOM) crea la primera TV de una sociedad Medica . Pharma Mar junto a otras 11 Farmas Oncolgicas lo Financian .
*.- Para ver el canal TV SEOM ... pikar en el titular .
*.- Más info : http://www.elsemanaldigital.com/articulos.asp?idarticulo=92585
Yondelis en Combinacion con Capecitabine . Nueva Patente conseguida .
COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO-DRUGS FOR THE TREATMENT OF CANCER
Publication number: HR20080598 (T3)
Publication date: 2009-01-31
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: HR20080000598T 20081202
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115
Abstract not available for HR 20080598 (T3)
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m<2> for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
Publication number: HR20080598 (T3)
Publication date: 2009-01-31
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: HR20080000598T 20081202
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115
Abstract not available for HR 20080598 (T3)
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m<2> for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
Yondelis activo contra el Cancer de Melanoma . EPAR EMEA pag . 4 .
Melanoma , esta indicacion consta en la Propia EMEA .... en el EPAR de la aprobación del Yondelis STS .... ver pagina 4 .
Trabectedin binds to the minor groove of DNA, bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.
El gran problema del cáncer es que falta traducir lo que sabemos a fármacos .
María Blasco es directora del Programa de Oncología Molecular del Centro Nacional de Investigaciones Oncológicas (CNIO) y ha conseguido que su nombre destaque en letras mayúsculas en el mundo de la ciencia ...
Dia Mundial del Cáncer . Lo positivo es el Diagnóstico precoz .
Hoy, Día Mundial del Cáncer, aparentemente hay poco que celebrar. Los últimos datos apuntan a que uno de cada tres hombres y una de cada cuatro mujeres serán diagnosticados de cáncer a lo largo de su vida ...
Suscribirse a:
Entradas (Atom)